Novel Triple Agonist Nabs Biggest Weight Loss Yet in Obesity Trial
SAN DIEGO — An investigational triple-hormone receptor agonist yielded major weight loss in people with obesity, a phase II trial showed. By 24 weeks, patients on any of the four doses of once-weekly injectable retatrutide lost a significantly greater amount of weight than those on placebo — achieving the trial’s primary endpoint — reported Ania […]